within Pharmacolibrary.Drugs.ATC.L;

model L04AC11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 11 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004719999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00249,
    k12             = 0.36,
    k21             = 0.36
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AC11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Siltuximab is a chimeric (human-murine) monoclonal antibody that binds to human interleukin-6 (IL-6), a pro-inflammatory cytokine implicated in various inflammatory and neoplastic conditions. It is approved for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients (both sexes) with multicentric Castleman’s disease or solid tumors, receiving doses of siltuximab (11 mg/kg) by intravenous infusion.</p><h4>References</h4><ol><li><p>Mayer, CL, et al., &amp; Puchalski, TA (2015). Dose selection of siltuximab for multicentric Castleman&#x27;s disease. <i>Cancer chemotherapy and pharmacology</i> 75(5) 1037–1045. DOI:<a href=&quot;https://doi.org/10.1007/s00280-015-2720-0&quot;>10.1007/s00280-015-2720-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25784388/&quot;>https://pubmed.ncbi.nlm.nih.gov/25784388</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=&quot;https://doi.org/10.4161/19420862.2015.988944&quot;>10.4161/19420862.2015.988944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25484055/&quot;>https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li><li><p>Suzuki, K, et al., &amp; Iizuka, K (2015). Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. <i>International journal of hematology</i> 101(3) 286–294. DOI:<a href=&quot;https://doi.org/10.1007/s12185-015-1743-y&quot;>10.1007/s12185-015-1743-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25655379/&quot;>https://pubmed.ncbi.nlm.nih.gov/25655379</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AC11;
